Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

318 ARTÍCULOS , VIENDO DEL 196 AL 210

A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial

Cheng ST, Lau RW, Mak EP, Ng NS, Lam LC, Fung HH, Lai JC, Kwok T, Lee DT.

Trials. 2012 Jul 2;13:98. doi: 10.1186/1745-6215-13-98.

Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease

Sanchez-Ramos J, Cimino C, Avila R, Rowe A, Chen R, Whelan G, Lin X, Cao C, Ashok R.

J Alzheimers Dis. 2012;31(4):843-55. doi: 10.3233/JAD-2012-120196.

The essential dialogue: a Norwegian study of art communication in mental health care

Ingeberg MH, Wikstrøm BM, Berg A.

J Psychosoc Nurs Ment Health Serv. 2012 Aug;50(8):22-30. doi: 10.3928/02793695-20120703-01. Epub 2012 Jul 15.

Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY)

Waldorff FB, Buss DV, Eckermann A, Rasmussen ML, Keiding N, Rishøj S, Siersma V, Sørensen J, Sørensen LV, Vogel A, Waldemar G.

BMJ. 2012 Jul 17;345:e4693. doi: 10.1136/bmj.e4693.

Solving the puzzle of Alzheimer disease

Uriri-Glover J, McCarthy M, Cesarotti E.

Nurse Pract. 2012 Sep 10;37(9):20-7; quiz 27-8. doi: 10.1097/01.NPR.0000418381.60864.68.

[Dementia guidelines: what should come to general practice--an interdisciplinary consensus of physicians in private practice]

Riepe MW, Fellgiebel A; DEGAM, DGN, DGPPN.

Dtsch Med Wochenschr. 2012 Jul;137(30):1499-504. doi: 10.1055/s-0032-1305171. Epub 2012 Aug 6.

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.

Arch Neurol. 2012 Nov;69(11):1430-40. doi: 10.1001/archneurol.2012.2194.

The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E.

J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

NAPA 2.0: the next giant leap

Khachaturian AS, Paul SM, Khachaturian ZS.

Alzheimers Dement. 2012 Sep;8(5):379-80. doi: 10.1016/j.jalz.2012.08.002.

[Consensus 2012--diagnosis and treatment of patients with dementia in Switzerland]

Monsch AU, Büla C, Hermelink M, Kressig RW, Martensson B, Mosimann U, Müri R, Vögeli S, von Gunten A; Alzheimer Forum Schweiz.

Praxis (Bern 1994). 2012 Sep 19;101(19):1239-49. doi: 10.1024/1661-8157/a001085.

[Cognitive-behavioral specialized units in Alzheimer disease treatment: a necessity]

Paccalin M.

Geriatr Psychol Neuropsychiatr Vieil. 2012 Sep;10(3):233. doi: 10.1684/pnv.2012.0367.

Potential of drug-loaded nanoparticles for Alzheimer's disease: diagnosis, prevention and treatment

Doggui S, Dao L, Ramassamy C.

Ther Deliv. 2012 Sep;3(9):1025-7. doi: 10.4155/tde.12.84.

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort

Wattmo C, Wallin AK, Minthon L.

BMC Neurol. 2012 Nov 5;12:134. doi: 10.1186/1471-2377-12-134.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias